CORSEARCH
23.5.2024 14:44:27 CEST | Business Wire | Press release
Corsearch, the leading provider of brand protection and trademark solutions, has today shared research forecasting that the number of active global trademarks will surpass the 100 million mark by 2026, in just two years.
Data from the Corsearch TrademarkNow platform shows that there were 83,613,385 active trademarks at the end of 2023, predicted to rise to 88,072,867 by the end of this year. Corsearch calculations forecast that by 2026, this figure will reach 100,720,928 – an increase of over 150% from the 2016 figures from a decade prior.
This growth in active trademark volumes demonstrates the increasing number of intellectual properties being developed and used by organizations across the world, in addition to a growing focus on the importance of protecting your intangible assets.
Examining 2024 filing figures, Corsearch can reveal that the country with the most active companies filing trademarks is China, followed swiftly by the USA and Brazil. The UK ranks 8th globally and, of the EU, only France features in the top ten most active filing countries.
Trademark volume rankings by originating country, 2023 |
|
1. |
China |
2. |
USA |
3. |
Brazil |
4. |
India |
5. |
Turkey |
6. |
Mexico |
7. |
Japan |
8. |
United Kingdom |
9. |
Russia |
10. |
France |
In order to support in-house counsel and expert IP advisors through this period of significant growth, Corsearch has also today announced its next-generation TrademarkNow platform. Lightning-fast AI and insights from 1,000+ sources ensure comprehensive trademark searching and monitoring – upgrades include:
- 75% faster turnaround time for notices than other industry solutions. Automated and Expert Watch solutions offer options between AI technology to deliver efficient monitoring of trademarks in the face of expanding trademark portfolios without sacrificing accuracy, or bespoke strategies and focused insights for more complex, high-value matters
- 40% improvement in IP legal team speeds of delivery for brand name clearance, with Corsearch LogoCheck and Name Generator tools allowing better searching of existing brand identities in combination with AI suggestions of candidate names
- Industrial Designs can be searched faster and more accurately through new similarity algorithms and the Corsearch AI image recognition engine
- ExaMatch search modifiers and NameCheck reporting allow for more targeted search queries and customizable reports better fit for individual needs
Viji Krishnan, President of Trademark Solutions, Corsearch, commented:
“Over the past years, the world has been waking up to the importance of trademarking intangible assets and intellectual property, and the risks of not doing so. It’s no surprise that we are only a few years away from seeing over 100 million trademarks active across the globe. It’s an optimistic sign of the intense innovation fuelling global organizations and empowering global business.
“But as with most things: the higher the volume of actively registered trademarks, the greater the potential complexity for IP professionals. We’re delighted to be launching our next-generation TrademarkNow platform to help experts in our sector cut through the noise. New AI tools will operate at the sheer scale needed to manage the size of modern trademark portfolios, effective dashboards which help prioritize work and the combined human expertise of our analysts who average over 15 years’ experience, ensures that brands uphold trademark distinctiveness.”
Notes to Editors
Methodology
Corsearch calculations are based on the data sourced from the TrademarkNow™ global trademark platform spanning all global trademark offices and registries. Where applicable, the effects of COVID on trademark filing have been accounted for.
About Corsearch:
Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521172877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
